{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:17:06Z","timestamp":1794327426641,"version":"4.9.0"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Sleep Research"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Daridorexant, a dual orexin receptor antagonist, is approved for the treatment of insomnia disorder in adults. Approximately 30%\u201335% of patients with insomnia disorder also have obstructive sleep apnoea (OSA) of any severity. It is unclear whether sleep medications provide safe and effective treatment for insomnia in these patients. This post hoc analysis evaluated the efficacy and safety of daridorexant 25 and 50\u2009mg on objective and self\u2010reported insomnia variables and self\u2010reported daytime functioning in patients with untreated mild OSA and comorbid insomnia disorder (COMISA). This analysis included participants with insomnia disorder enrolled in the Phase 3 study assessing either daridorexant 25 or 50\u2009mg with an apnoea\/hypopnoea index 5\u2013&lt;\u200915\u2009events\/h (\u2018mild OSA\u2019). Wake after sleep onset (WASO), latency to persistent sleep (LPS), self\u2010reported total sleep time (sTST) and the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) were assessed at Months 1 and 3. Safety endpoints were treatment\u2010emergent adverse events, daytime somnolence and next\u2010morning residual effects. In participants with mild OSA, daridorexant improved WASO, LPS, sTST and IDSIQ total score over time. The average treatment effect size for all efficacy parameters was numerically greater with daridorexant 50\u2009mg than with daridorexant 25\u2009mg; daridorexant 25\u2009mg was not always greater than placebo. No safety concerns were reported for daridorexant 50 or 25\u2009mg. In participants with comorbid insomnia and untreated mild OSA, daridorexant 50\u2009mg versus placebo improved all sleep parameters over time and was well tolerated. Daridorexant warrants further investigation in COMISA.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    identifier: NCT03545191\n                  <\/jats:p>","DOI":"10.1111\/jsr.70135","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T06:19:28Z","timestamp":1752560368000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Effects of Daridorexant on Patients With Comorbid Insomnia Disorder and Untreated Mild Obstructive Sleep Apnoea: A Post Hoc Subgroup Analysis of a Phase 3, Randomised Clinical Trial"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-2908","authenticated-orcid":false,"given":"Christopher J.","family":"Lettieri","sequence":"first","affiliation":[{"name":"Idorsia Pharmaceuticals US Ltd  Radnor Pennsylvania USA"},{"name":"Pulmonary, Critical Care and Sleep Medicine, Department of Medicine Uniformed Services University  Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orestis","family":"Briasoulis","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd  Allschwil Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"L\u00e9ger","sequence":"additional","affiliation":[{"name":"VIFASOM (Vigilance Fatigue et Sant\u00e9 Publique) Universit\u00e9 Paris Cit\u00e9  Paris France"},{"name":"APHP, H\u00f4tel Dieu de Paris Centre du Sommeil et de la Vigilance  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre\u2010Philippe","family":"Luyet","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd  Allschwil Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Louis","family":"P\u00e9pin","sequence":"additional","affiliation":[{"name":"Grenoble Alpes University  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-7679","authenticated-orcid":false,"given":"Stuart F.","family":"Quan","sequence":"additional","affiliation":[{"name":"Division of Sleep and Circadian Disorders, Department of Medicine Brigham and Women's Hospital and Division of Sleep Medicine, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Raphelson","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine University of California, San Diego  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Saskin","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals US Ltd  Radnor Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine University of California, San Diego  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"e_1_2_13_2_1","volume-title":"Prescribing Information","author":"AMBIEN (Zolpidem Tartrate)","year":"2022"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_2_13_4_1","volume-title":"Prescribing Information","author":"ATIVAN (Lorazepam)","year":"2023"},{"key":"e_1_2_13_5_1","volume-title":"The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications","author":"Berry R. B.","year":"2017"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa275"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2023.11.1026"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101492"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/2589977515666221108093830"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.6988"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201404\u20100718OC"},{"key":"e_1_2_13_12_1","volume-title":"FDA Medical Queries (FMQs)","author":"FDA US Food and Drug administration","year":"2022"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.3514"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.181.4102.856"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271\u2010020\u201000474\u2010z"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsab142"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13563"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2024.07.019"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011090.pub2"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00027406"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00436\u20101"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsmc.2022.03.003"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0000000000001182"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005113421901"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290\u2010023\u201000484\u2010w"},{"key":"e_1_2_13_27_1","volume-title":"Prescribing Information","author":"QUVIVIQ (Daridorexant)","year":"2022"},{"key":"e_1_2_13_28_1","volume-title":"Summary of Product Characteristics","author":"QUVIVIQ (Daridorexant)","year":"2022"},{"key":"e_1_2_13_29_1","volume-title":"Public Summary SwissPAR","author":"QUVIVIQ (Daridorexant)","year":"2022"},{"key":"e_1_2_13_30_1","volume-title":"Product Monograph","author":"QUVIVIQ (Daridorexant)","year":"2023"},{"key":"e_1_2_13_31_1","volume-title":"Prescribing Information United Kingdom","author":"QUVIVIQ (Daridorexant)","year":"2024"},{"key":"e_1_2_13_32_1","volume-title":"Product Information","author":"QUVIVIQ (Daridorexant)","year":"2024"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14035"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13604"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2016.07.002"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/mcp.0000000000001007"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci9120371"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101519"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.241596"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2019.01.004"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27186041"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.7112"}],"container-title":["Journal of Sleep Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jsr.70135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jsr.70135","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jsr.70135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:18:02Z","timestamp":1790313482000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jsr.70135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/jsr.70135"],"URL":"https:\/\/doi.org\/10.1111\/jsr.70135","archive":["Portico"],"relation":{},"ISSN":["0962-1105","1365-2869"],"issn-type":[{"value":"0962-1105","type":"print"},{"value":"1365-2869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"2025-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70135"}}